Data / Form D filings / Rapamycin Holdings, Inc.
Rapamycin Holdings, Inc.: Form D filings
Rapamycin Holdings, Inc., a pharmaceuticals company in San Antonio, TX, filed 7 Form D notices with the SEC between 2013 and 2019. The latest, on June 18, 2019, reports an offering of $7 million with nothing sold yet.
Find out what Rapamycin Holdings, Inc. does, who founded it and who invested, beyond what the filing says. $10 of credit on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads every Form D on SEC EDGAR the day it is filed, and this page is that reading. Ask for your own cut (a state, an industry, a size) and new filings arrive in your sheet, CRM, Slack or agent as they land.
Company details from the filing
- Address
- 16601 BLANCO RD. SUITE #120, San Antonio, TX, 78232
- Phone
- (210) 381-2486
- Industry
- Pharmaceuticals
- Entity type
- Corporation
- Incorporated in
- Delaware
- Revenue range
- $1 - $1,000,000
- Exemptions claimed
- Rule 506(c)
- SEC identifier (CIK)
- 1582949
The full lists. Form D filings in Texas: 4,800 rows, $128, or the new rows each week for $19 a month. Form D filings in Pharmaceuticals: 346 rows, $17.30, or the new rows each week for $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (company, CIK, year incorporated, street, city, state and 5 more), which open on your screen as soon as the payment clears and come by email. For agents and scripts: every list with its row count and price is at https://specstream.ai/data/lists.json.
Form D filings
| Filed | Type | Offering | Sold | Remaining | Investors | First sale | Filing |
|---|---|---|---|---|---|---|---|
| Jun 18, 2019 | New notice | $7,000,000 | $0 | $7,000,000 | 0 | Yet to occur | sec.gov |
| Feb 16, 2018 | New notice | $1,500,000 | $0 | $1,500,000 | 0 | Yet to occur | sec.gov |
| Aug 25, 2017 | New notice | $3,500,000 | $0 | $3,500,000 | 0 | Yet to occur | sec.gov |
| Apr 18, 2016 | New notice | $2,000,000 | $0 | $2,000,000 | 0 | Yet to occur | sec.gov |
| Jul 22, 2014 | New notice | $2,500,000 | $0 | $2,500,000 | 0 | Yet to occur | sec.gov |
| Feb 3, 2014 | Amendment | $1,426,094 | $1,426,094 | $0 | 18 | Jul 16, 2013 | sec.gov |
| Jul 31, 2013 | New notice | $900,000 | $616,094 | $283,906 | 8 | Jul 16, 2013 | sec.gov |
Executive officers and directors named in the filing
| Name | Role | Note in the filing |
|---|---|---|
| Stephen Dufilho | Director | |
| Spangler Vaughn Carole | Executive Officer | |
| Mark Horsey | Executive Officer |
Other pharmaceuticals companies in Texas that filed recently
- LUCIER PHARMACEUTICALS INC offering · Oct 13, 2026
- FibroBiologics, Inc. $1.2 million · Oct 13, 2026
- Eos SENOLYTIX, Inc. $750,000 · Aug 27, 2026
Every Form D from the week of Jun 17, 2019 · All recent filings in Texas · All recent Pharmaceuticals filings
Read from SEC EDGAR. Amount sold is what Rapamycin Holdings, Inc. reported on the day it filed; on an offering that is still open, a later amendment can raise it. Free to reuse with credit to SpecStream under CC BY 4.0.
$10 of credit on sign-up, no card.